Table 1

Survey results

N (%)
Age (years)
 <3048 (13.9)
 30–60227 (65.8)
 >6070 (20.3)
 Female311 (90.2)
 Rheumatoid arthritis177 (51.3)
 Systemic lupus erythematosus86 (24.9)
 Primary Sjögren’s syndrome19 (5.5)
 Axial spondyloarthritis14(4)
 Psoriatic arthritis10 (2.9)
 Inflammatory myopathies8 (2.3)
 Scleroderma8 (2.3)
 Vasculitis5 (1.5)
 Other*18 (5.2)
Indicated treatment
 Synthetic DMARDs195 (56.5)
 Biologic and target DMARDs25 (7.2)
 Combined therapy (biologic and synthetic) DMARDs27 (7.8)
 Chloroquine, hydroxychloroquine90(26)
 Glucocorticoids139 (40.3)
 NAIDs16 (4.6)
Behaviours answers
 Without changes in their indicated medication286 (82.9)
 Without changes in their indicated medication but thinking of suspending7 (2)
 Change in their medication (dose reduction, periodicity decrease or application delay)22 (6.4)
 Suspension of the indicated medication17(5)
 Suspension of the indicated medication and restart before the survey13 (3.7)
Changed or suspended treatment
 Synthetic DMARDs15 (28.8)
 Biologic and target DMARDs8 (15.3)
 Combined therapy (biologic and synthetic) DMARDs4 (7.7)
 Chloroquine, hydroxychloroquine25 (48.1)
 Glucocorticoids10 (19.2)
 NAIDs1 (1.2)
Reasons for changes or suspension of their medication
 Lack of availability25 (48.1)
 Fear of getting sick from COVID-1913(25)
 Indication of the rheumatologist4 (7.7)
 Indication of other clinicians3 (5.8)
 Economic reason2 (3.8)
 Other5 (9.6)
  • Synthetic DMARDs: methotretaxe, leflunomide, sulfasalazine, mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus. Biologic and target DMARDs: certolizumab, adalimumab, golimumab, rituximab, tocilizumab, belimumab, abatacept, baricitinib, tofacitinib.

  • *Other: juvenile idiopathic arthritis, mixed connective tissue disease, undifferentiated connective tissue disease, Still disease, primary antiphospholipid syndrome.

  • DMARDs, disease-modifying antirheumatic drugs; NAIDs, non-steroidal anti-inflammatory drugs.